Background. Gastrointestinal motility disorder is a common gastrointestinal disease, which seriously affects life quality. Traditional Chinese medicine (TCM) has been widely used as an alternative therapy for gastrointestinal motility disorder. Acacetin is a natural flavonoid compound that has antioxidant and anti-inflammatory, antidepressant, and anticancer properties. However, the efficacy of Acacetin in the treatment of gastrointestinal motility disorders has not been studied. Our aim was to investigate the mechanism of Acacetin-alleviated gastrointestinal motility disorder and its efficacy based on network pharmacology. Methods. We performed network pharmacology to predict the active components, match Weishu decoction (WSD) targets in gastrointestinal motility disorders, and investigate its potential pharmacological mechanisms. We performed the GO and KEGG enrichment analysis. In vivo, we investigated the effects of Acacetin in the gastrointestinal motility disorder model. Results. Based on network pharmacological method, the key active ingredient of WSD was identified as Acacetin, and the enrichment signaling pathway was the PI3K-AKT signaling pathway. Acacetin and Mosapride accelerated gastric emptying time, reduced gastric remnant rate, and increased small intestinal propulsion rate. The levels of GAS and MTL were increased after using Acacetin. These results indicated that Acacetin could improve gastrointestinal motility disorders. Among them, high-dose Acacetin showed a better effect. Acacetin could regulate protein and lipid metabolism in mice with gastrointestinal motility disorder. Furthermore, Acacetin could modulate gastrointestinal inflammation and apoptosis. The detection of the PI3K-AKT signaling pathway-related proteins showed that Acacetin improved gastrointestinal motility disorder by inhibiting the activation of the PI3K-AKT signaling pathway. Conclusion. The key ingredient Acacetin in WSD could alleviate gastrointestinal motility disorder by inhibiting the activation of the PI3K-AKT signaling pathway based on network pharmacology analysis. The efficacy and safety of Acacetin treatment provide strong experimental support for the clinical treatment of gastrointestinal motility disorder.

中文翻译：

---

基于网络药理分析的胃舒汤关键成分金合欢素缓解胃肠动力障碍

背景。胃肠动力障碍是一种常见的胃肠道疾病，严重影响生活质量。中药（TCM）已被广泛用作胃肠动力障碍的替代疗法。金合欢素是一种天然类黄酮化合物，具有抗氧化和抗炎、抗抑郁和抗癌特性。然而，尚未研究金合欢素治疗胃肠动力障碍的功效。我们的目的是基于网络药理学研究金合欢素减轻胃肠动力障碍的机制及其疗效。方法. 我们进行了网络药理学来预测活性成分，匹配胃舒汤 (WSD) 在胃肠动力障碍中的靶点，并研究其潜在的药理机制。我们进行了 GO 和 KEGG 富集分析。在体内，我们研究了金合欢素在胃肠动力障碍模型中的作用。结果. 基于网络药理学方法鉴定出WSD的关键活性成分为Acacetin，富集信号通路为PI3K-AKT信号通路。Acacetin 和 Mosapride 加速胃排空时间，减少胃残留率，增加小肠推进率。使用 Acacetin 后 GAS 和 MTL 水平增加。这些结果表明，Acacetin 可以改善胃肠动力障碍。其中，大剂量的Acacetin效果更好。金合欢素可以调节胃肠动力障碍小鼠的蛋白质和脂质代谢。此外，Acacetin 可以调节胃肠道炎症和细胞凋亡。结论。基于网络药理学分析，WSD中的关键成分Acacetin可通过抑制PI3K-AKT信号通路的激活来缓解胃肠动力障碍。Acacetin治疗的有效性和安全性为胃肠动力障碍的临床治疗提供了强有力的实验支持。